Oil-Depot Type Bleomycin in the Treatment of Malignant Lymphoma in Comparison with Regular Bleomycin

Oil-depot type bleomycin was originally intended to take advantageof not only concentration-dependent action, but also the time-dependentaction of bleomycin to obtain more efficient tumor cell kill.In this study, the effects of oil-depot type bleomycin and regularbleomycin on 81 patients with malignant lymphoma were compared.Both oil-depot type bleomycin and regular bleomycin were equallyeffective against Hodgkin's disease, with a complete remissionrate of 60% (6/10) and 54.5% (6/11), respectively. Non-Hodgkin's lymphoma in advanced stages responded better tooil-depot type bleomycin [complete remission (CR); 35.2% (6/17)]than to regular bleomycin [CR: 10.5% (2/19)]. In addition, thepatients were more responsive to smaller doses of oil-depottype bleomycin than regular bleomycin. Eleven out of 12 (91.6%)patients who responded to oil-depot type bleomycin, went intocomplete remission before receiving 45 mg in total dosage ofbleomycin, while five out of 10 (50%) patients who respondedto regular bleomycin reached complete remission after 60 mgin total dosage was administered. The toxic manifestations of oil-depot type bleomycin were almostthe same in quality and quantity as regular bleomycin. However,the average total dose of oil-depot type bleomycin used wasalmost half of that of regular bleomycin. ^* Present address: Cancer Chemotherapy Center, Cancer ResearchInstitute, Tokyo, Japan.^** Present address: National Nagoya Hospital, Nagoya, Japan.